Core Insights - Johnson & Johnson announced updated results from the Phase 3 CARTITUDE-4 study, indicating that at least 80% of standard-risk patients with relapsed or refractory multiple myeloma remained progression and treatment-free after a single infusion of CARVYKTI as early as second-line treatment [1][2][3] - The study suggests that stronger immune fitness in patients treated earlier may correlate with longer progression-free survival [1][3] Group 1: Study Results - In the CARTITUDE-4 study, 80% of as-treated patients with standard-risk cytogenetics did not experience disease progression at 30 months following CARVYKTI infusion [1][2] - Among 176 patients treated with CARVYKTI as early as second line, the 30-month progression-free survival (PFS) rate for standard-risk patients was 80.5% [2] - All patients (100%) who achieved minimal residual disease-negative complete response at 12 months remained progression-free at 30 months [2] Group 2: Immune Fitness and Treatment Paradigm - Translational analyses indicated that patients receiving CARVYKTI after one or two prior lines of therapy exhibited stronger immune fitness compared to those with three or more prior lines [3] - The findings support a shift in treatment paradigm, emphasizing the importance of early intervention for achieving deeper and more durable responses in multiple myeloma [2][3] Group 3: Broader Implications - Johnson & Johnson is collecting and analyzing clinical and real-world data to further understand long-term remission outcomes and safety trends associated with CARVYKTI [4] - The comprehensive experience from over 9,000 patients treated globally provides a foundation for expanding CARVYKTI's use into earlier treatment settings [4]

Core Insights - Johnson & Johnson announced long-term follow-up data from the CARTITUDE-1 study, showing that 33% of patients with relapsed or refractory multiple myeloma treated with CARVYKTI® achieved progression-free survival of five years or more with a single infusion [1][3][4] - The CARTITUDE-4 analysis demonstrated significant overall survival and progression-free survival benefits across various patient subgroups, including those with standard and high-risk cytogenetics [1][5] Group 1: CARTITUDE-1 Study Findings - In the CARTITUDE-1 study, 32 out of 97 patients (33%) achieved progression-free survival for at least five years after receiving CARVYKTI® [1][3] - The median overall survival for patients in the study was reported at 60.7 months, indicating a durable response to the treatment [3] - Among the patients who remained progression-free, the majority had undergone a median of six prior lines of therapy, with 90.6% being triple-class refractory [3][7] Group 2: Safety Profile - The safety profile of CARVYKTI® in the CARTITUDE-1 study remained consistent with previous findings, with no new safety signals identified [4] - Two new cases of second primary malignancies were reported, but no new cases of Parkinsonism or cranial nerve palsies were observed [4] - The incidence of cytokine release syndrome (CRS) was noted in 84% of patients, with 4% experiencing Grade 3 or higher CRS [21] Group 3: CARTITUDE-4 Study Insights - The CARTITUDE-4 study, presented at the ASCO Annual Meeting, showed that CARVYKTI® improved progression-free survival and overall survival compared to standard care in various patient subgroups [5][9] - The study included patients with relapsed and lenalidomide-refractory multiple myeloma who had received one to three prior lines of therapy [9] Group 4: Future Directions - Johnson & Johnson is focusing on shifting treatment strategies from managing progression to aiming for a cure in multiple myeloma [6] - Upcoming presentations at the European Hematology Association (EHA) 2025 Congress will further discuss the findings from the CARTITUDE studies [6]